Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 7 briefings matching “glp-1”

Reset all filters

Endocrinology

Endocrinology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

ENDOCRINOLOGY · CLINICAL PRACTICE

Ozempic in Pregnancy: Diabetes, Not Drug, Linked to Early Births?

The reason you're taking Ozempic or Wegovy matters during pregnancy, with underlying diabetes potentially posing a greater risk than the medication itself. This study challenges the previously held, often generalized, assumption that GLP-1 medications alone are responsible for pregnancy complications.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 13, 2026

ENDOCRINOLOGY · PHASE III

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

In Japanese adults with obesity disease, once-daily orforglipron resulted in statistically superior reductions in bodyweight versus placebo (inactive comparison treatment), with a safety profile consistent with that of other GLP-1 receptor agonists. Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across Phase 3 trials globally.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Diabetes & EndocrinologyOct 30, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Analysis Asks: Are GLP-1 Drugs Safe in People With Frailty?

This Medical News article discusses an analysis of cardiovascular benefits and safety of semaglutide use in trial participants with frailty, defined by accumulated age-related health deficits. Published in JAMA, these peer-reviewed endocrinology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readJAMAOct 30, 2026

ENDOCRINOLOGY · PHASE I/II

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events. To evaluate the efficacy (real-world effectiveness in the trial) and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readDiabetes CareOct 28, 2026

ENDOCRINOLOGY · GUIDELINE / OPINION

The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO

We take a critical historical perspective, charting the highs and lows of obesity medication development and examining the scientific, regulatory, and societal factors that have slowed or impeded the translation of pharmacological advances into safe, effective, and widely accepted treatments for obesity. Reflecting this paradigm shift, WHO issued global guidelines and included GLP-1 receptor agonists in the Essential Medicines List, albeit for a narrowly defined population.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Diabetes & EndocrinologyOct 19, 2026

ENDOCRINOLOGY · RANDOMIZED CLINICAL TRIAL

Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women

Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readNature MedicineOct 16, 2026

ENDOCRINOLOGY · PHASE III

UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial

UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile, supporting Phase 3 evaluation. UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readCell MetabolismOct 8, 2026

Interactive Fact Check